long intergenic non-protein coding RNA 678Genealiases: []
Q-omics provides the consensus-scored LINC00678 profile across patient tissues and cancer cell-line models. LINC00678 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, LINC00678 is differentially expressed in 1, with the highest sampling consensus in BRCA. Additionally, LINC00678 RNA expression shows 7,450 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LUSC, BRCA, and TGCT as cancer lineages where LINC00678 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC00678 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC00678 survival associations across molecular data types. LINC00678 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC00678 RNA expression–survival associations across cancer types. High LINC00678 expression shows unfavorable associations in LUSC, THCA, SKCM, MESO and ACC, but favorable associations in BRCA. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .014). Together, the overview and detailed table identify LUSC as the clearest survival context for LINC00678 RNA expression.
This table summarizes LINC00678 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC00678. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC00678 shows higher tumor expression in BRCA. The BRCA box plot shows higher LINC00678 RNA expression in tumor versus normal tissue (log2 FC = +0.106, t-test p = .015).
This table shows molecular features associated with LINC00678 in patient tissues and cancer cell lines. In patient samples, LINC00678 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
